Cargando…

Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community

BACKGROUND AND OBJECTIVES: The current clinical course descriptors of multiple sclerosis (MS) include a combination of clinical and magnetic resonance imaging (MRI) features. Recently there has been a growing call to base these descriptors more firmly on biological mechanisms. We investigated the im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thompson, Alan J, Moccia, Marcello, Amato, Maria Pia, Calabresi, Peter A, Finlayson, Marcia, Hawton, Annie, Lublin, Fred D, Marrie, Ruth Ann, Montalban, Xavier, Panzara, Michael, Sormani, Maria Pia, Strum, Jon, Vickrey, Barbara G, Coetzee, Timothy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Future Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580678/ https://www.ncbi.nlm.nih.gov/pubmed/37691493 http://dx.doi.org/10.1177/13524585231196786

Ejemplares similares

Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal
por: Thompson, Alan J, et al.
Publicado: (2021)

Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance
por: Zackowski, Kathleen M, et al.
Publicado: (2021)

Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approach—perspectives from the International Progressive MS Alliance
por: Zaratin, Paola, et al.
Publicado: (2022)

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
por: Walton, Clare, et al.
Publicado: (2020)

The 2013 clinical course descriptors for multiple sclerosis: A clarification
por: Lublin, Fred D., et al.
Publicado: (2020)

Landscape of MS patient cohorts and registries: Recommendations for maximizing impact
por: Bebo, Bruce F, et al.
Publicado: (2017)

Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities
por: Motl, Robert W, et al.
Publicado: (2017)

Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG
por: Waubant, Emmanuelle, et al.
Publicado: (2019)

The Barancik lecture: Comorbidity in multiple sclerosis—Looking backward, looking forward
por: Marrie, Ruth Ann
Publicado: (2023)

Pathways to cures for multiple sclerosis: A research roadmap
por: Bebo, Bruce F, et al.
Publicado: (2022)

Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment
por: Cohen, Jeffrey A, et al.
Publicado: (2019)

Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO
por: Sormani, Maria Pia, et al.
Publicado: (2017)

Lung involvement correlates with disability in MS patients with COVID-19 pneumonia
por: Immovilli, Paolo, et al.
Publicado: (2022)

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Assessing kidney stone composition using smartphone microscopy and deep neural networks
por: Onal, Ege Gungor, et al.
Publicado: (2022)

Different MRI patterns in MS worsening after stopping fingolimod
por: Lapucci, Caterina, et al.
Publicado: (2019)

Brief International Cognitive Assessment for MS (BICAMS): international standards for validation
por: Benedict, Ralph HB, et al.
Publicado: (2012)

Prioritizing the healthcare access concerns of Canadians with MS
por: Pétrin, Julie, et al.
Publicado: (2021)

Enhancing diversity of clinical trial populations in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

Direct Prediction of Physicochemical Properties and Toxicities of Chemicals from Analytical Descriptors by GC–MS
por: Zushi, Yasuyuki
Publicado: (2022)

Assessing heterogeneity of treatment effect in multiple sclerosis trials
por: Sormani, Maria Pia, et al.
Publicado: (2023)

Serum antibodies to phosphatidylcholine in MS
por: Sádaba, Maria Cruz, et al.
Publicado: (2020)

Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS
por: Harel, Asaff, et al.
Publicado: (2016)

A Hybrid Approach for MS Diagnosis Through Nonlinear EEG Descriptors and Metaheuristic Optimized Classification Learning
por: Mohseni, Elnaz, et al.
Publicado: (2022)

Building Research Support Capacity across Human Health Biobanks during the COVID-19 Pandemic
por: Byrne, Jennifer A, et al.
Publicado: (2021)

Moving with the Times: The Health Science Alliance (HSA) Biobank, Pathway to Sustainability
por: Quinn, Carmel M, et al.
Publicado: (2021)

Mind Over Matter: Confronting Challenges in Post-Mortem Brain Biobanking for Glioblastoma Multiforme
por: Griffin, Cassandra, et al.
Publicado: (2021)

What is Kindness in Science and why does it matter?
por: Boulter, Jessica, et al.
Publicado: (2022)

The relationship between cortical lesions and periventricular NAWM abnormalities suggests a shared mechanism of injury in primary-progressive MS
por: Pardini, Matteo, et al.
Publicado: (2017)

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
por: Havrdova, Eva, et al.
Publicado: (2017)

Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art Review
por: Behrouzi, Bahar, et al.
Publicado: (2020)

Serum neurofilament light chain in relapsing-remitting MS: Unchaining disease activity prediction?
por: Marrie, Ruth Ann
Publicado: (2017)

Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week
por: Kawakami, Rika, et al.
Publicado: (2021)

Cerebellar volume as imaging outcome in progressive multiple sclerosis
por: Inglese, Matilde, et al.
Publicado: (2017)

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS
por: Ribbons, Karen Ann, et al.
Publicado: (2015)

Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS
por: Fox, Edward J., et al.
Publicado: (2019)

An Italian programme for COVID-19 infection in multiple sclerosis
por: Sormani, Maria Pia
Publicado: (2020)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Sharing data from MS clinical trials: Opportunities, challenges, and future directions
por: Coetzee, Timothy
Publicado: (2015)

Comparison of Flow Injection-MS/MS and LC-MS/MS for the Determination of Ochratoxin A
por: Zhang, Kai
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s3o971kd1l49slbgkl87i0karo